News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase III
Cyclacel Pharma (CYCC) Crashes as Leukemia Drug Flunks Key Late-Stage Trial 2/23/2017
Novartis AG (NVS)'s Cancer Drug Gets a Fast Track Ticket From the FDA 2/23/2017
AVEO Oncology (AVEO) Announces TIVO-3 Passes The First Safety Monitoring Committee Safety Review 2/23/2017
Tocagen Receives Breakthrough Therapy Designation From FDA For Toca 511 & Toca FC In Recurrent High Grade Glioma 2/23/2017
Roche (RHHBY) Reports Death in Phase III Hemophilia Study 2/23/2017
VBI Vaccines Receives Positive Response From Health Canada’s Initial Evaluation Of The Proposed Sci-B-Vac Phase III Clinical Program 2/22/2017
Committee Recommends Discontinuation of Argos (ARGS)' Phase III Renal Cell Carcinoma Study 2/22/2017
Why ImmunoGen (IMGN) Investors are Waiting on Bated Breath to Move "FORWARD" 2/22/2017
Massachusetts' Agenus (AGEN) Quietly Discloses Failure of Cancer Vaccine Trial 2/22/2017
SAGE Therapeutics (SAGE) Takes Investors On A Wild Ride As CEO Talks Up Brain Drugs 2/22/2017
This Drug Could Rattle Biogen (BIIB) and Be the Next Billion-Dollar Blockbuster for Celgene (CELG) 2/21/2017
Trevena (TRVN)'s Painkiller Oliceridine Succeeds in Two Phase III Studies 2/21/2017
Boston Biomedical Initiates Canstem111p: A Global Phase III Study Investigating Cancer Stemness Inhibitor Napabucasin In Patients With Metastatic Pancreatic Cancer 2/21/2017
GenSight Biologics Completes Enrollment Of REVERSE Phase III Study Of GS010 In The Treatment Of Leber’s Hereditary Optic Neuropathy 2/21/2017
3 Biotechs With the Biggest and Most Promising Pipelines 2/20/2017
AstraZeneca PLC (AZN) Investors Pumped as Breast Cancer Drug Sails Through Phase III Trial 2/20/2017
After Merck & Co. (MRK) & Eli Lilly (LLY) Alzheimer’s Failures, A Look at 7 Companies Still on the Hunt 2/20/2017
Janssen Biotech (JNJ) Release: New Data Shows STELARA (ustekinumab) Maintained Clinical Response And Remission After Two Years Of Treatment In Adult Patients With Moderately To Severely Active Crohn's Disease 2/17/2017
Janssen-Cilag International NV (JNJ) Presents Newly-Published Data On The Use Of ZYTIGA (Abiraterone Acetate) Plus Prednisone In The Real-World, Outside The Clinical Trial Setting1 2/17/2017
Takeda (TKPYY) And TiGenix Report New Data Highlighting Maintenance Of Long-Term Remission Of Complex Perianal Fistulas In Crohn’s Disease Patients With Cx601 2/17/2017
Aimmune (AIMT) Provides Update On Ongoing AR101 Phase 3 Program For Peanut Allergy Based On FDA Feedback 2/17/2017
Myriad Genetics (MYGN)’s Bracanalysis CDx Test Successfully Identified Metastatic Breast Cancer Patients With Improved Outcomes From AstraZeneca PLC (AZN)'s PARP Inhibitor, Olaparib 2/17/2017
ArQule (ARQL), Daiichi Sankyo's Liver Cancer Drug Comes Up Short in Another Phase III Study 2/17/2017
Sought-After Tesaro (TSRO) Sees A $5 Billion Opportunity For Its Cancer Drug 2/17/2017
Pfizer (PFE) Release: New Data In Crohn’s Disease Patients Shows Similar Efficacy And Safety Profiles For INFLECTRA And REMICADE 2/17/2017
Celltrion Healthcare (068270.KQ) Releases Positive Results From Pivotal Study In Crohn’s Disease 2/17/2017
AstraZeneca PLC (AZN) Release: Updated Durvalumab Monotherapy Data Confirm Results In Urothelial Bladder Cancer 2/17/2017
Immune Pharma Announces The Launch Of REMAIN, An International Overall Survival Study With Ceplene And Low Dose Proleukin In Remission Maintenance In Acute Myeloid Leukemia 2/17/2017
Denovo Biopharma Plans To Initiate A Global Phase III Trial Of DLBCL Drug 2/17/2017
Celgene (CELG) Announces Positive Results From Phase III SUNBEAM Trial Of Oral Ozanimod In Patients With Relapsing Multiple Sclerosis 2/17/2017
Bay Area Biotech Ardelyx (ARDX) Rejoices as Lead Drug Hits Phase III Goals 2/16/2017
Pfizer (PFE) Announces Top-Line Results From The Oral Strategy Trial Of XELJANZ (Tofacitinib Citrate) Compared To Humira (Adalimumab) 2/16/2017
Amgen (AMGN)’s Repatha CVOT Results Are Potential Game-Changer For Lipid-Lowering Treatment 2/16/2017
Eli Lilly (LLY) Release: Additional Results From Pivotal RA-BEAM Study Published In The New England Journal of Medicine Show Baricitinib-Treated Patients Demonstrated Sustained Improvement In Rheumatoid Arthritis Compared To Adalimumab And Placebo 2/16/2017
Denovo Biopharma Plans To Launch A Global Phase III Trial Of DB102 (Enzastaurin) In Diffuse Large B-Cell Lymphoma 2/16/2017
City of Hope To Manufacture NurOwn For BrainStorm Cell's Phase III ALS Clinical Trial 2/16/2017
TRACON Pharma (TCON) Announces First Patient Dosed In Phase III TAPPAS Trial Of TRC105 In Angiosarcoma 2/16/2017
Merck & Co. (MRK)'s Alzheimer's Failure Has All Eyes and Hopes Turning to Biogen (BIIB) 2/16/2017
Roche (RHHBY) Faces Off With Itself for $9 Billion Breast Cancer Drug Business 2/15/2017
2 Biotechs Taking on the $20 Billion Alzheimer's Market Full Force 2/15/2017
Gilead (GILD) Announces 144-Week Data Evaluating Safety And Efficacy Of Genvoya For Treatment Of HIV-1 In Treatment-Naïve Adults 2/15/2017
Theratechnologies (TH.TO) Announces New Data From The Pivotal Phase III Trial Of HIV Monoclonal Antibody And Long-Acting Investigational Antiretroviral Ibalizumab 2/15/2017
Merck & Co. (MRK)’s Doravirine, An Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) For The Treatment Of HIV-1 Infection, Met Primary Efficacy Endpoint In Pivotal Phase III Trial 2/15/2017
First Patient Enrolled In NovoCure’s Phase III Pivotal LUNAR Trial Testing Tumor Treating Fields For The Treatment Of Advanced Non-Small Cell Lung Cancer After Failing Platinum-Based Therapy 2/15/2017
Amgen (AMGN)’s Repatha CVOT Results Are Potential Game-Changer For Lipid-Lowering Treatment 2/15/2017
Allergan (AGN) R&D Chief Reveals 6 Drugs That Could be Potential Blockbusters 2/14/2017
Gilead (GILD) Looks Over Its Shoulder as GlaxoSmithKline (GSK) Gains Ground With New HIV Phase III Trial Data 2/14/2017
Armetheon Announces EMA's Support For 1000 Patient Single Phase lll Study Prior To MAA Filing For Its Novel Oral Anticoagulant Tecarfarin 2/14/2017
Ohr Pharma (OHRP) Pauses Enrollment of Phase III Trial of Its Lead Drug 2/14/2017
Janssen Announces Two-Drug Combination Of Dolutegravir And Rilpivirine Demonstrates Efficacy In Maintaining Viral Suppression In Phase III Clinical Studies 2/14/2017
Axsome (AXSM) Receives FDA Fast Track Designation For AXS-05 For Treatment Resistant Depression 2/14/2017
Global Blood Therapeutics (GBT) Announces Publication Of Paper Describing Discovery Of GBT440 In American Chemical Society Medicinal Chemistry Letters 2/14/2017
SAVSU Provides Performance Update On Evo Cold Chain 2.0 System In ImmunoCellular Therapeutics (IMUC) Phase lll Glioblastoma Cell Therapy Clinical Trial 2/14/2017
RedHill Biopharma (RDHL) Announces Enrollment Of Last Patient In BEKINDA Phase III Study For Acute Gastroenteritis 2/13/2017
Bay Area's Zosano (ZSAN) Surges After Migraine Patch Hits Goals in Late-Stage Study 2/13/2017
Why Intercept Pharma (ICPT) Stock Jumped Nearly 10% On Friday After Providing Phase III Update 2/13/2017
Acacia Pharma Announces Positive Results From Its Fourth And Final Pivotal Trial Of BAREMSIS For The Rescue Treatment Of PONV 2/13/2017
eMD Release: Cladribine Tablets Significantly Reduced Brain Atrophy In Patients With Multiple Sclerosis 2/13/2017
Resverlogix (RVX.TO) Highlights Unique Properties Of Apabetalone In Both A Rare Muscular Dystrophy (FSHD) And Neurodegenerative Eye Disease 2/13/2017
Zogenix (ZGNX) Announces Initiation Of Clinical Efficacy Portion Of Study 1504 For ZX008 In Dravet Syndrome 2/13/2017
Neurocrine Biosciences (NBIX) Nabs North American Rights to Bial's ONGENTYS 2/10/2017
AVEO Oncology (AVEO) Announces Clinical And Regulatory Updates For Tivozanib 2/10/2017
Seattle Genetics (SGEN) Reports Fourth Quarter And Year 2016 Financial Results 2/10/2017
Acorda (ACOR) Rockets After Parkinson's Drug Hits Late-Stage Goals 2/10/2017
Armetheon Reaches Agreement With FDA To Conduct A 1000 Patient Single Phase 3 Study Prior To NDA Filing For Its Novel Oral Anticoagulant Tecarfarin 2/9/2017
Promising Phase III Data for Bayer (BAY)’s Xarelto Leads to Early Halt of Study 2/9/2017
New FDA Report Cites 22 Drugs That Passed Phase II But Crashed and Burned in Phase III 2/8/2017
H. Lundbeck A/S (LUN.CO) Throws in the Towel on Alzheimer's Pill, Giving Leeway to Rival Axovant (AXON) 2/8/2017
Onxeo: Information On ReLive Trial Design And Role Of Its Data Safety And Monitoring Board 2/8/2017
Can-Fite BioPharma (CFBI) Gears Up For ACRobat, Its Phase III Trial Of Piclidenoson In Rheumatoid Arthritis 2/8/2017
GlaxoSmithKline (GSK)'s Incoming CEO Preps for Deals, R&D Decisions on New Drugs 2/7/2017
Mithra Pharmaceuticals Completes Recruitment For European Phase III Estelle Study 2/7/2017
Biofrontera AG Reports Positive Phase III Results For Ameluz In Combination With Daylight-PDT 2/7/2017
VBI Vaccines Receives Positive EMA Scientific Advice Regarding Sci-B-Vac Phase III Clinical Study 2/7/2017
Taxus Cardium (CRXM) Release: FDA Grants Fast Track Designation To Angionetics' Generx Product Candidate, A One-Time Gene Therapy For Coronary Heart Disease 2/7/2017
Why Struggling Alkermes (ALKS) Could Make a Comeback in 2017 2/7/2017
FDA Lifts Clinical Hold on NW Bio (NWBO)'s Phase III Cancer Vaccine Trial 2/7/2017
Synergy Pharma (SGYP) Release: Pivotal Phase III Data Results For TRULANCE (Plecanatide) In The Treatment Of Chronic Idiopathic Constipation (CIC) Published In American Journal Of Gastroenterology 2/7/2017
AstraZeneca PLC (AZN) Quietly Kills Some Programs 2/6/2017
These 5 Biotechs Are Battling Over the $10 Billion Hemophilia Market 2/6/2017
Kiadis Pharma Issues Clinical And Regulatory Progress Update On ATIR101 And ATIR201 2/6/2017
5 Daring Biopharmas Mixing Drugs With Marijuana 2/6/2017
Amgen (AMGN)'s Cholesterol-Lowering Drug Repatha Wows in Huge Heart Study 2/3/2017
Eli Lilly (LLY) Washes Its Hands of Another Phase 3 Study After the Failure of Solanezumab 2/2/2017
AstraZeneca PLC (AZN) Investors Nervous as Its Recovery Hinges on the Success of New Meds and Key Drug Data 2/2/2017
Sobi - Long-Term Safety And Efficacy Data Of Extended Half-Life Therapy Alprolix In Children With Haemophilia B Published In The Lancet Haematology 2/2/2017
Nabriva Confirms No Sample Size Adjustment Required For LEAP 1 Phase III Trial Of Lefamulin In Community Acquired Bacterial Pneumonia 2/2/2017
Bioverativ (BIVVV) Release: Long-Term Safety And Efficacy Data Of Extended Half-Life Therapy ALPROLIX In Children With Hemophilia B Published In The Lancet Hematology 2/2/2017
Meet This Largely Over-Looked Phase 3 Alzheimer's Company 2/1/2017
Radius Health (RDUS) Release: Mayo Clinic Proceedings Publishes Positive Results From The Activextend Clinical Trial Of Abaloparatide-SC In Postmenopausal Women With Osteoporosis 2/1/2017
Collegium (COLL) Announces Positive Topline Results Of Human Abuse Potential Clinical Trial Evaluating The Oral Abuse Of Xtampza ER 2/1/2017
6 Biopharma Companies Face Catalysts in February 1/31/2017
Repros Therapeutics (RPRX) Release: FDA Grants End Of Phase 2 Meeting To Discuss Phase 3 Requirements For Oral Proellex In The Treatment Of Uterine Fibroids 1/31/2017
Motif BioSciences, Inc. Phase 3 Clinical Trial Finishes Patient Treatment Phase 1/31/2017
Tenax Therapeutics (TENX)'s Phase 3 LEVO-CTS Trial in Cardiac Surgery Did Not Achieve Dual Endpoint 1/31/2017
AEterna Zentaris (AEZS) Announces Completion Of Zoptrex Pivotal Phase 3 Clinical Trial In Advanced Endometrial Cancer; Expects To Report Top-Line Results In April 2017 1/31/2017
FibroGen (FGEN)'s Novel Anemia Treatment Meets Phase III Endpoints In China 1/31/2017
FDA Approves Allergan (AGN)'s sNDA For AVYCAZ (Ceftazidime And Avibactam) To Include New Phase III Data In Patients With Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis 1/30/2017
Rigel (RIGL) Release: Fostamatinib Study Results Continue To Trend Positive 1/30/2017
X4 Pharma Announces Initiation Of A Phase 2/3 Clinical Study Of X4P-001-LD In Patients With WHIM Syndrome, A Rare Genetic Primary Immunodeficiency Disease 1/30/2017
BrainStorm Cell Announces Validation Of NurOwn Cryopreservation Process 1/30/2017
Foresee Pharma Announces Top-Line Results from Phase 3 Registration Study in Advanced Prostate Cancer 1/27/2017
Amgen (AMGN) Receives Positive CHMP Opinion For Abp 501 (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases 1/27/2017
Novan Reports Topline Results From SB204 Phase 3 Pivotal Trials 1/27/2017
Aurinia (AUPH) Selects Worldwide Clinical Trials As Its CRO For Phase 3 Lupus Nephritis Trial 1/27/2017
ImmunoGen (IMGN) Announces First Patient Dosed In FORWARD I Phase 3 Study Of Mirvetuximab Soravtansine In Platinum-Resistant Ovarian Cancer 1/27/2017
Celgene (CELG) Receives Positive CHMP Opinion To Expand REVLIMID (Lenalidomide) Indication As Monotherapy For The Maintenance Treatment Of Patients With Newly Diagnosed Multiple Myeloma (MM) After Autologous Stem Cell Transplantation 1/27/2017
Aldeyra (ALDX) Release: Biotech Announces Clinical Development Update For Phase 3 Programs 1/25/2017
Myovant Release: Initiates Phase 3 Clinical Program Of Relugolix In Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids 1/25/2017
ImmuPharma plc (IMM.L) Release: Company Update On Lupuzor Pivotal Phase III Study Full Analysis Of Patient Recruitment 1/25/2017
Novartis AG (NVS) Shows Off 13 Potential Blockbusters in Pipeline 1/25/2017
Esperion (ESPR) Release: Pharma Completes Enrollment Of Pivotal Phase 3 Long-Term Safety And Tolerability Study Of Bempedoic Acid In Patients With Hypercholesterolemia 1/25/2017
Eisai Inc. (ESALF.PK) Release: Positive Topline Results Of Large Phase 3 Trial Show Pharma's Lenvatinib Meets Primary Endpoint In Unresectable Hepatocellular Carcinoma 1/25/2017
Genmab A/S (GEN.CO) Release: Company Provides Clinical And Regulatory Update For NCX 470 For IOP Lowering 1/24/2017
OSE Immunotherapeutics Release: Company Announces That The Independent Data Monitoring Committee (IDMC) Recommends Continuation Of Pivotal Phase 3 Clinical Trial Of Tedopi In Non-Small Cell Lung Cancer 1/24/2017
Onxeo Release: Company Completes Enrollment In Phase 3 Study Of Livatag For The Treatment Of Hepatocellular Carcinoma 1/24/2017
Genentech (RHHBY) Release: FDA Grants Priority Review for Actemra to Treat Giant Cell Arteritis 1/24/2017
Success of Pfizer (PFE)’s Humira Biosimilar for Rheumatoid Arthritis in Phase III Bodes Well for Its Strong Biosimilar Pipeline 1/23/2017
Actelion (ALIOF.PK) Release: Amid Takeover Talks With Johnson & Johnson (JNJ), The Company's Hypertension Drug Flunks Key Phase III Test 1/23/2017
Kamada Ltd. (KMDA) Release: Company Announces Positive Scientific Advice Response From The EMA Focused On Alpha-1 Antitrypsin IV For Treatment Of Acute Graft-Versus-Host Disease 1/23/2017
Bristol-Myers Squibb (BMY) Release: Company Falls Behind Rival Merck & Co. (MRK), Will Not Pursue Faster Approval for Lung Cancer Combo 1/20/2017
Dermira (DERM), UCB Group (UCBJF.PK) Release: Companies' Psoriasis Drug Wows In Phase III Study, Eyes Q3 Filing 1/19/2017
Synthetic Biologics (SYN) Release: Company Confirms Key Features Of Pivotal Phase 2b/3 Trial Of SYN-010 Pursuant To Consultations With FDA 1/19/2017
Bristol-Myers Squibb (BMY) Release: Company's Opdivo (Nivolumab) Demonstrated Efficacy And Improved Survival In Patients With Previously Treated Advanced Gastric Cancer In A Randomized Phase III Study 1/19/2017
Zavante Therapeutics Release: Company Reports Completion Of Patient Treatment In The ZEUS Study Of ZTI-01 (fosfomycin for injection) For The Treatment Of Complicated Urinary Tract Infections 1/19/2017
ImmunoGen (IMGN) CEO Sees Potential in Company’s Lead ADC Product 1/18/2017
New Grunenthal CEO Forges Ahead with Treatment for Complex Regional Pain Syndrome 1/18/2017
How This Israeli Biotech Could be a Threat to Celgene (CELG) 1/18/2017
Jazz Pharma (JAZZ) Release: Company Announces First Patient Enrolled In Phase 3 Clinical Trial Evaluating Defibrotide For The Potential Prevention Of VOD In High Risk Patients 1/18/2017
Global Blood Therapeutics (GBT) Release: Company Announces Enrollment Of First Patient In Phase III HOPE Study In Sickle Cell Disease 1/18/2017
Paratek Pharma (PRTK) Release: Company Announces Completion Of Enrollment In Omadacycline Phase III Community-Acquired Bacterial Pneumonia Study 1/18/2017
Elite Pharma (ELI) Release; Company Reports Positive Topline Results From A Pivotal Bioequivalence Study For A Generic Oxycontin 1/17/2017
TetraPhase (TTPH) Doses First Patient In IGNITE3 Phase III Clinical Trial Of Once-Daily IV Eravacycline In cUTI 1/17/2017
AstraZeneca PLC (AZN) Release: Biopharma Rejigs Primary Endpoints for Mystic Lung Cancer Trial 1/17/2017
Alcobra (ADHD) Release: Company Stock Decimated As ADHD Drug Flunks Phase III Test 1/17/2017
Allergan (AGN), Gedeon Richter (RIG2.F) Release: Companies Show Off Late-Stage Uterine Fibroids Data 1/17/2017
Pluristem Therapeutics (PSTI) Release: Company Receives Clearance From Germany To Initiate Its Multinational Phase III Trial In Critical Limb Ischemia Targeting Early Conditional Marketing Approval 1/17/2017
JPM17: Why the Key to Gene Therapy Could be in an Old Bay Area Warehouse 1/16/2017
Sunovion Release: Biopharma Announces Pivotal Study Results For Novel Drug Candidate Dasotraline Demonstrating Significantly Improved Attention Deficit Hyperactivity Disorder Symptoms In Children Compared To Placebo 1/16/2017
New Spinraza Data Has Biogen (BIIB) Screaming 'It's Worth It!' 1/16/2017
JPM17: Opko Health (OPK) CEO's Gameplan After Its Recent Growth Hormone Failure 1/13/2017
Sunovion Release: Massachusetts Biotech Touts Binge Eating and ADHD Mid-Stage Trials Data 1/13/2017
Shionogi Release: Pharma's Investigators are Prepping a FDA App for New Antibiotic After Positive Trial 1/13/2017
JPM17: New Biogen (BIIB) CEO on Groundbreaking Alzheimer's Trial and the Company's Future 1/12/2017
Advanced Accelerator Applications Release: Biotech Announces The New England Journal of Medicine Publication Of Lutathera NETTER-1 Phase III Results 1/12/2017
Trevena (TRVN) Release: Company Completes Phase 3 Apollo Trials For Oliceridine, Says Athena Study On Track 1/12/2017
Augmenix Release: Company Announces Positive Three-Year Long-Term Data Highlighting Benefits Of Spaceoar Hydrogel Spacer For Patients With Prostate Cancer 1/12/2017
Starpharma Release: VivaGel BV Granted QIDP And Fast Track Designation By U.S. FDA 1/12/2017
Keryx (KERX) Release: Biopharma Announces Publication Of Auryxia (Ferric Citrate) Phase III Trial Results For Iron Deficiency Anemia (IDA) In Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) In Journal Of The American Society Of Nephrology 1/12/2017
JPM17: Aurinia (AUPH)’s CEO on a Mission to Improve the Way Lupus Nephritis is Treated 1/11/2017
Vtesse Announces Dosing Of First Patient In Australia In Phase 2b/3 Clinical Trial Of VTS-270 In Niemann-Pick Type C1 Disease 1/11/2017
Tonix Pharma (TNXP) Release: Company Presented Details Of Newly Expanded Product Development Pipeline At 9th Annual Biotech Showcase Conference 1/11/2017
Amgen (AMGN) Release: Study Results Published In JAMA Show Company's Parsabiv (Etelcalcetide) Significantly Reduced Serum Parathyroid Hormone In Adults With Secondary Hyperparathyroidism On Hemodialysis 1/11/2017
CytoDyn (CYDY) Release: Biotech Files For Breakthrough Therapy Designation With The FDA For PRO 140 In HIV Therapy 1/11/2017
Affimed (AFMD) Release: Biopharma Provides Update On NK-Cell Immuno-Oncology Platform 1/11/2017
Citius Pharma Release: Company's Mino-Lok Addresses Resistant Pathogens 1/11/2017
RedHill Biopharma (RDHL) Release: Pharma Announces QIDP Fast-Track Designation Granted By FDA To RHB-104 For Nontuberculous Mycobacteria Infections 1/11/2017
TherapeuticsMD (TXMD) Release: Company Announces Publication Of Two Manuscripts On The Rejoice Trial For TX-004HR In Leading Peer-Reviewed Medical Journal 1/11/2017
NICO Corporation Release: Company Announces First Patient Enrolled In Phase 3 Randomized Controlled Trial On Early Intervention Of Hemorrhagic Stroke, Deadliest Form Of Stroke 1/10/2017
Pluristem Therapeutics (PSTI) Release: Jumps as the FDA Clears Critical Limb Ischemia Trial 1/10/2017
Halozyme (HALO) Release: Pharma Company Provides Program Updates, 2017 Financial Guidance At 35th Annual JP Morgan Healthcare Conference 1/10/2017
Valeant (VRX) Release: Pharma Company Announces Results Of Second Phase 3 Study For Psoriasis Treatment IDP-118 1/10/2017
RedHill Biopharma (RDHL) Release: Pharma Announces First Dosing In RHB-105 Supportive PK Studies Ahead Of Confirmatory Phase III Study For H. Pylori Infection 1/10/2017
Pluristem Therapeutics (PSTI) Release: Company’s Phase III Study Of PLX-PAD Cells For The Treatment Of Critical Limb Ischemia Cleared By U.S. FDA 1/10/2017
AbbVie (ABBV)'s HCV Drug Shows 99% Cure Rate In Study 1/9/2017
Lipocine (LPCN) Receives FDA Guidance On The Phase III Program For LPCN 1107, An Oral Alternative For The Prevention Of Preterm Birth 1/9/2017
Alcobra (ADHD) Provides Update On Recent FDA Meeting And Path Forward For MDX Clinical Development Program 1/9/2017
Adamas Pharma (ADMS) Outlines Key 2017 Priorities And Highlights 2016 Achievements 1/9/2017
Esperion (ESPR) Announces Initiation Of Three Pivotal Phase 3 Studies For Bempedoic Acid 1/9/2017
PTC Therapeutics (PTCT) Provides Corporate Update And Outlines 2017 Strategic Priorities To Maximize The Global Value Of Translarna And Advance Its Innovative Pipeline 1/9/2017
Enanta Pharmaceuticals, Inc. Announces High SVR12 Rates Achieved In Genotype 1 Chronic HCV Infected Japanese Patients With Eight Weeks Of Treatment With Abbvie’s Investigational, Pan-Genotypic, Ribavirin-Free Regimen Of Glecaprevir/Pibrentasvir (G/P) 1/9/2017
Incyte (INCY) And Merck & Co. (MRK) To Advance Clinical Development Program Investigating The Combination Of Epacadostat With KEYTRUDA (Pembrolizumab) 1/9/2017
Acceleron Pharma Outlines Corporate Goals And Priorities For 2017 1/6/2017
Alexion (ALXN) Release: FDA Grants Orphan Drug Designation To ALXN1210 For The Treatment Of Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) 1/6/2017
Orexigen (OREX) Announces Publication Of Contrave (Naltrexone Hcl And Bupropion Hcl Extended-Release Tablets) Real-World Study Results In "Obesity" 1/6/2017
CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib 1/5/2017
Soligenix (SNGX) Receives Positive Scientific Advice From The EMA For SGX942 In The Treatment Of Oral Mucositis In Head And Neck Cancer Patients 1/5/2017
Otonomy (OTIC) Announces Positive Top-Line Results From Phase III Clinical Trial of OTIPRIO in Patients With Acute Otitis Externa 1/5/2017
Rigel (RIGL) Provides Business Updates And Preliminary Data In IgA Nephropathy 1/5/2017
Aevi Genomic Medicine Announces Completion Of Enrollment For Phase 2/3 SAGA Clinical Trial Of AEVI-001 (NFC-1) In mGluR+ ADHD Adolescents 1/5/2017
AEterna Zentaris (AEZS) Crashes on Disappointing Phase III Data 1/5/2017
Sun Pharma (SUNPHARMA.NS) Announces Positive Topline Results Of Confirmatory Phase-3 Clinical Trial For Seciera For Treatment Of Dry Eye 1/4/2017
FDA Grants Bayer (BAY) Priority Review For Stivarga (Regorafenib) For The Second-Line Systemic Treatment Of Liver Cancer 1/4/2017
CytRx (CYTR) Granted Type B Pre-NDA Meeting With U.S. FDA For Registration Pathway With Aldoxorubicin As A Treatment For Patients With Relapsed Soft Tissue Sarcomas 1/4/2017
Trevena (TRVN) Completes Enrollment Of Phase III APOLLO Pivotal Efficacy Trials Of Oliceridine For Moderate-To-Severe Acute Pain 1/4/2017
NeuroRx Announces FDA IND Clearance For NRX-101 Phase 2b/3 Study And Publication Of Promising Biomarker Data 1/4/2017
Agile Therapeutics, Inc. Announces Positive Top-line Phase III Results 1/4/2017
Ocular Therapeutix (OCUL) Jumps on More Positive Study Data for Dextenza 1/4/2017
Inotek (ITEK) Plunges On Failed Phase III Glaucoma Trial 1/3/2017
Ardelyx (ARDX) Announces Initiation Of Two Clinical Trials For RDX7675 For Treatment Of Hyperkalemia 1/3/2017
Axsome (AXSM) Receives FDA Clearance Of IND For Phase II/III Trial Of AXS-05 In Alzheimer’s Disease Agitation 1/3/2017
TRACON Pharma (TCON) Receives Special Protocol Assessment (SPA) Agreement From FDA For Phase III Clinical Trial Of TRC105 In Angiosarcoma 1/3/2017
Dermira (DERM) Initiates Phase III Clinical Program In Acne 1/3/2017
Phase III Flop for Pfizer (PFE)'s Drug Partner Opko Health (OPK) 1/3/2017
4 Fatal Deaths in Seattle Genetics (SGEN)' Early-Stage Trials of AML Drug 12/30/2016
Anthera Pharma (ANTH) Plunges After Cystic Fibrosis Drug Fails Late-Stage Trial 12/29/2016
Galena Biopharma  (GALE) Stocks Jump After FDA Meeting, Blood Cancer Therapy GALE-401 to Enter Phase III 12/28/2016
The 7 Worst Clinical Disasters of 2016 12/27/2016
After Fraud Probe, Alexion (ALXN) Reports Failed Soliris Trial 12/27/2016
ARMO BioSciences' Immunotherapy AM0010 Receives Orphan Designation In Europe For The Treatment Of Pancreatic Cancer 12/27/2016